Publications by authors named "Lorin A Ferris"

Claim this Profile
E
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
Risa L Wong, Lorin A Ferris, Olivia A Do, Sarah K Holt, Jorge D Ramos

Oncologist· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens.
Olivia A Do, Lorin A Ferris, Sarah K Holt, Jorge D Ramos, Lauren C Harshman

Clin Genitourin Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.
Ibiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, Jessica J Lin, Emily Chin, Lorin A Ferris

J Thorac Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Jessica J Lin, Emily Chin, Beow Y Yeap, Lorin A Ferris, Vashine Kamesan

J Thorac Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, Chiara Ambrogio, Lorin A Ferris

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in -Mutant Non-Small Cell Lung Cancer.
Varuna Nangia, Faria M Siddiqui, Sean Caenepeel, Daria Timonina, Samantha J Bilton, Lorin A Ferris

Cancer Discov· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, Beow Y Yeap, Ashish Saxena, Lorin A Ferris

J Thorac Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer.
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Lorin A Ferris

Cancer Discov· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
Ibiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, Catarina D Campbell, Jessica J Lin

JCO Precis Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in -Positive Non-Small-Cell Lung Cancer.
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Lorin A Ferris

JCO Precis Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, Mark Bailey, Alexa B Schrock, Lorin A Ferris

J Thorac Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis